港股異動丨百威亞太一度跌超7%,Q2股東應占溢利同比減少8.63%
百威亞太(1876.HK)盤初一度跌超7%至8.81港元,股價創逾1個月新低。百威亞太公佈截至6月底止中期業績,股東應占溢利5.41億美元,同比下跌5.91%,每股基本盈利4.1分;不派息。股東應占正常化溢利則為5.52億美元,同比減少4.66%。單計第二季,股東應占溢利2.54億美元,同比減少8.63%;股東應占正常化溢利則為2.55億美元,同比下滑8.6%。上半年,收入按年縮減7.28%至33.99億美元。總銷量46.57億公升,同比跌5.83%,總銷量減少是受中國行業表現放緩的影響,但部分被韓國及印度的強勁表現所抵消。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.